on March 7, 2018 Cerus Corporation (NASDAQ: CERS) reported that William ‘Obi’ Greenman, Cerus’ president and chief executive officer, is scheduled to present a corporate update at the Cowen and Company 38th Annual Health Care Conference at 8:00 am ET on Tuesday, March 13, 2018 (Press release, Cerus, MAR 7, 2018, View Source [SID1234524479]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available from the Investor Relations page of the Cerus web site at View Source A replay will be available for approximately two weeks following the completion of the event.

On March 7, 2018 Actinium Pharmaceuticals, Inc. (NYSE AMERICAN:ATNM) ("Actinium" or "the Company"), reported that it will be attending and presenting at the 30th Annual ROTH Conference being held on March 11-14, 2018 at the Ritz Carlton in Dana Point, California (Press release, Actinium Pharmaceuticals, MAR 7, 2018, View Source [SID1234524477]). Details of Actinium’s presentation are as follows:

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Date: Tuesday, March 13, 2018
Time: 11:00 AM PT
Room: Yellow – Salon 6
Venue: The Ritz Carlton Hotel

Management will conduct 1-on-1 meetings with investors during the conference. To arrange a meeting with Actinium please contact, Steve O’Loughlin, Actinium’s Principal Financial Officer at [email protected].

About 30th Annual ROTH Conference

30th Annual ROTH Conference scheduled for March 11-14, 2018 at The Ritz Carlton, Laguna Niguel in Orange County, CA. Following the success of the previous year’s events, the ROTH Conference, with close to 550 participating companies and over 4,700 attendees, will feature presentations from public and private companies in a variety of sectors including:

Business Services
Cleantech, Industrial Growth & Solar
Consumer
Healthcare
Resources: Oil & Gas / Metals & Mining
Technology, Internet & Media
This gathering of institutional investors, private equity investors, VCs and executives, and service providers has become a must-attend event for anyone working in the small and mid-cap space.

On March 6, 2018 Apexigen, Inc., a clinical-stage biopharmaceutical company, and the Pediatric Brain Tumor Consortium (PBTC), reported a clinical trial collaboration to evaluate Apexigen’s APX005M, an investigational immune activating compound that targets CD40, in pediatric patients with recurrent or refractory brain tumors (Press release, Apexigen, MAR 6, 2018, View Source [SID1234591002]). CD40 is an immune co-stimulatory receptor essential to the activation of both innate and adaptive immune responses against cancer. There is an unmet need in pediatric oncology for effective treatments for Central Nervous System (CNS) tumors. Immunotherapy is currently considered a promising area of investigation in clinical oncology and it is expected that novel immune-activating agents such as APX005M will provide additional benefit to complement the currently used immune checkpoint inhibitors.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The PBTC will conduct a Phase 1 dose escalation trial of APX005M in children at its participating academic medical centers and children’s hospitals across the United States. Objectives of the study include establishing the safety, tolerability, pharmacokinetics and preliminary evidence of activity for APX005M in the pediatric population. Ira Dunkel, M.D., Chairman of the PBTC Steering Committee, said, "We believe that CD40 activation is a very promising area of immunotherapy for cancer, and we are happy to be collaborating with Apexigen to evaluate APX005M in our pediatric patients."

"In a Phase 1 study, APX005M has demonstrated immune stimulation in adult patients with solid tumors," said Xiaodong Yang, M.D., Ph.D., President and CEO of Apexigen. "We are excited about the opportunity to collaborate with the PBTC to explore the effects of treatment with APX005M in this underserved pediatric population."

APX005M is a novel, humanized investigational monoclonal antibody designed to overcome the systemic immune suppression that typically affects cancer patients through activation of CD40, a co-stimulatory receptor on the antigen presenting cells that is essential for activating both innate and adaptive immunity.

On March 6, 2019 Calithera Biosciences, Inc. (Nasdaq:CALA), a clinical-stage biotechnology company focused on the development of novel cancer therapeutics, reported that Susan M. Molineaux, Ph.D, the company’s Founder, President and Chief Executive Officer, will present at the Cowen & Company 38th Annual Health Care Conference at 10:40 a.m. ET on Tuesday, March 13, 2018 in Boston (Press release, Calithera Biosciences, MAR 6, 2018, View Source [SID1234535244]). The presentation will be webcast live and available for replay for up to 30 days at www.calithera.com in the Investor Relations section.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Protalix has filed a 10-K – Annual report [Section 13 and 15(d), not S-K Item 405] with the U.S. Securities and Exchange Commission .

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!